WiserAD Trial Tests Whether Online Support Can Make Antidepressant Deprescribing Safer in Primary Care
Long-term antidepressant use has become a routine part of primary care, yet routine review does not always keep pace with prescribing. The WiserAD trial is built around that gap: a structured online support tool intended to help adults with mild or no depressive symptoms taper and stop antidepressants with clinical guidance, rather than drifting on treatment indefinitely.
The protocol sets out a pragmatic randomized controlled trial in Australian primary care that will compare the online intervention with usual care. Its central question is blunt and clinically familiar—can a guided deprescribing pathway help patients who no longer need antidepressants stop them safely, while maintaining low symptom burden and avoiding relapse?
A Primary Care Population Already Past the Acute Treatment Phase
The study enrolls adults aged 18 to 75 years who have taken antidepressant medication for more than 12 months and who currently have mild to no symptoms of depression. That selection matters because it focuses the trial on patients for whom continued prescribing may no longer match current clinical need. In everyday practice, these are often the patients who stay on medication because no one has clearly started the conversation about stopping.
The protocol also addresses a broader public health issue. When antidepressants are continued without a clear ongoing indication, patients may shoulder unnecessary exposure to adverse effects, pill burden, cost, and the psychological message that treatment must continue indefinitely. At the system level, long-term prescribing without structured review adds avoidable cost and can crowd out more appropriate care.
How the Trial Is Designed to Test Deprescribing in the Real World
The study uses a stratified, single-blind, parallel-group, two-arm superiority design. A total of 340 eligible participants will be randomized 1:1 to either the active intervention or an attention control group, with stratification by general practice or state of residence for participants recruited through social media. This is a pragmatic design, so the emphasis is on how the intervention performs in ordinary primary care rather than in a tightly controlled specialist setting.
Participants in the active arm will be asked to reduce antidepressant use with help from the WiserAD online support tool. Participants in the control arm will continue usual care. Both groups will receive information about antidepressants through the Beyond Blue website, a choice that helps limit the possibility that any observed benefit is driven simply by access to basic education.
That structure turns the comparison toward the clinical value of active, guided deprescribing support rather than generic information alone.
The Primary Endpoint Puts Mood Stability and Stopping Success in the Same Frame
The primary outcome is the between-arm difference in the proportion of participants who successfully cease medication use at 6 months and have mild or absent depressive symptoms. That endpoint is clinically sensible because discontinuation alone is not enough. A patient can stop an antidepressant and still be left with significant mood symptoms; equally, symptom stability without deprescribing would not answer the core medication question.
By pairing cessation with maintained low symptom severity, the trial is testing a more meaningful bedside outcome: whether deprescribing can be accomplished without sacrificing mental health stability. The emphasis on 6 months captures the period when tapering, withdrawal symptoms, and early recurrence are most likely to become apparent.
Follow-up Extends Beyond the Taper Window
Participants will be followed at 3, 6, 12, and 18 months, allowing investigators to track antidepressant use, depression and anxiety symptom severity, quality of life, and health economic data over time. This longer horizon is important because successful discontinuation is not a single event. It is a process that can unfold across dose reduction, symptom monitoring, adjustment of expectations, and the possibility of reinitiating therapy if clinically necessary.
The trial also includes intention-to-treat analysis, preserving the randomized comparison even when participants do not follow the assigned pathway perfectly. In deprescribing research, that approach is especially relevant because real-world adherence to taper plans is often uneven. Patients may reduce more slowly than intended, pause, or stop and restart depending on symptoms and life circumstances.
Cost-Effectiveness Is Central, Not Secondary
The protocol does not confine itself to symptom outcomes. Cost-consequence and cost-utility analyses will examine whether the intervention changes quality of life and whether the online support tool offers economic value relative to usual care. That decision reflects how deprescribing programs are judged in routine practice: an intervention that is clinically acceptable but resource-intensive may be difficult to scale, while a low-cost digital tool could be adopted more widely if the outcome balance proves favorable.
A digital model also has an obvious practical appeal in primary care. General practitioners often manage limited consultation time and wide clinical demand, leaving little room for prolonged taper counseling. An online tool that can structure dose reduction, reinforce follow-up, and standardize patient education could reduce some of that burden if the trial shows benefit.
Recruitment Reached Full Target After Ongoing Enrollment
Funding from the National Health and Medical Research Council was secured in 2019. By submission of the manuscript in July 2025, 310 participants had been randomized and recruitment was ongoing. The target of 340 randomized participants was reached in January 2026, and outcomes are scheduled for peer-reviewed publication in February 2027.
Those dates place the study squarely in the implementation window where protocol quality matters. The intervention will only be as useful as the clinical pathway it supports: tapering guidance, symptom monitoring, and enough support to keep both patients and clinicians confident while antidepressants are reduced.
Why This Trial Could Change Routine Deprescribing Conversations
Antidepressant deprescribing often fails for a simple reason. Clinicians worry about recurrence, patients worry about withdrawal, and the plan never fully gets started. By combining online guidance with primary care oversight, WiserAD is attempting to make stopping a medication as deliberate as starting one.
If the intervention improves the proportion of patients who can cease antidepressants while remaining well, it would support a more active deprescribing model in general practice. If it does not, the field will have a cleaner answer about the limits of digital support alone. Either way, the trial addresses a common clinical problem with a design that measures both symptoms and the economics of care, which is where deprescribing decisions are ultimately made.